Standard BioTools Beheer

Beheer criteriumcontroles 2/4

De CEO Standard BioTools is Adam Taich, benoemd in Mar2023, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.13% van de aandelen van het bedrijf, ter waarde $ 501.15K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2 jaar en 4 jaar.

Belangrijke informatie

Adam Taich

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	4yrs

Recente managementupdates

Recent updates

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

Dec 19

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Nov 10

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Apr 17

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Apr 02

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Oct 14

CEO

Adam Taich (47 yo)

less than a year

Tenure

Mr. Adam Taich was Executive Vice President of Life Sciences Business Unit at Standard BioTools Inc. (formerly known as SomaLogic, Inc.) since August 2022 until March 28, 2023 and serves as its Interim Chi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Stephen Williams	Chief Medical Officer	15yrs	US$2.55m	0.085% $ 336.3k
Adam Taich	Interim CEO	less than a year	geen gegevens	0.13% $ 501.1k
Pi Zheng	Interim Chief Accounting Officer	less than a year	geen gegevens	geen gegevens
Jason Cleveland	Chief Technology Officer	3yrs	geen gegevens	geen gegevens
Nebojsa Janjic	Chief Science Officer	15yrs	geen gegevens	geen gegevens
Ruben Gutierrez	General Counsel	2yrs	geen gegevens	0.059% $ 232.1k
Alison Roelke	Chief People Officer	2yrs	geen gegevens	0.0091% $ 36.0k
Shane Bowen	Chief Research & Development Officer	less than a year	geen gegevens	geen gegevens

2.0yrs

Gemiddelde duur

48.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SLGC wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Richard Post	Independent Director	4.3yrs	US$202.07k	0.030% $ 120.6k
Craig Mundie	Member of Advisory Board	no data	geen gegevens	geen gegevens
Eli Casdin	Independent Director	3.1yrs	US$197.57k	0.0018% $ 7.2k
Jason Ryan	Independent Chairman	less than a year	geen gegevens	geen gegevens
Thomas Carey	Independent Director	less than a year	geen gegevens	geen gegevens
Troy Cox	Independent Director	2.3yrs	US$2.59m	0.042% $ 164.7k
Anne Marguiles	Independent Director	4.3yrs	US$204.70k	0.012% $ 49.2k
Peter Ganz	Member of Medical Advisory Board	4yrs	geen gegevens	geen gegevens
Rosalind Raine	Member of Medical Advisory Board	4yrs	geen gegevens	geen gegevens
Marc Feldmann	Member of Medical Advisory Board	4yrs	geen gegevens	geen gegevens
Michael Blum	Member of Medical Advisory Board	4yrs	geen gegevens	geen gegevens
John Tooke	Member of Medical Advisory Board	4yrs	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SLGC wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Standard BioTools Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

Somalogic, Inc. Announces Chief Financial Officer Changes

Less than half of directors are independent

High number of new and inexperienced directors

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

Consensus estimates of losses per share improve by 10%

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Somalogic, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 21% to US$3.93

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Less than half of directors are independent

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

Price target decreased to US$6.50

SomaLogic, Inc. Announces the Full-Scale Global Launch of the SomaLogic Certified Site Program

Consensus forecasts updated

High number of new and inexperienced directors

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2022

SomaLogic, Inc. to Report Q3, 2022 Results on Nov 14, 2022

SomaLogic, Inc. Announces the Appointment of Troy Cox as Executive Chairman of the Board of Directors

SomaLogic appoints former Foundation Medicine chief as executive chair

Melody Harris to Leave SomaLogic, Inc. as President and Chief Operating Officer, Effective August 31, 2022

Consensus forecasts updated

SomaLogic Provides Revenue Guidance for the Full Year 2022

Price target decreased to US$7.75

Price target decreased to US$11.50

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into an agreement to acquire Palamedrix, Inc. for $52.5 million.

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

SomaLogic, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SomaLogic, Inc. Announces Resignation of Stephen Quake from the Board of Directors, Effective July 17, 2022

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Price target decreased to US$14.50

SomaLogic, Inc. Provides Revenue Guidance for the Full Year 2022

High number of new and inexperienced directors

SomaLogic, Inc., Annual General Meeting, Jun 06, 2022

SomaLogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Independent Director exercised options to buy US$275k worth of stock.

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

Now 24% undervalued after recent price drop

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

SomaLogic, Inc. to Report Q4, 2021 Results on Mar 29, 2022

SomaLogic, Inc. Provides Revenue Guidance for the Year 2022

SomaLogic Announces That the Company Will Begin Assaying Samples from the Multi-Ethnic Study of Atherosclerosis (Mesa) Study Beginning in the First Quarter of 2022

Oncohost Ltd. Announces Interim Results from PROPHETIC Trial, Multicenter Assessment of NSCLC Patient Response to Immunotherapy

SomaLogic, Inc. Revises Revenue Guidance for the Year Ended December 31, 2021

High number of new and inexperienced directors

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.55 loss per share

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Director recently bought US$160k worth of stock

No independent directors

CEO